Seasons Greetings, Fans of Mendelspod!

As we approach the end of 2023, we want to thank all our new subscribers for your support!   This has been a tough year in the precision medicine industry.   Sponsorships are down, and we had to turn to you, the audience, for support to ensure our success.  And you’re answering the call.  Thank you. This will guarantee quality and independent shows and will ensure our ability to explore new and other topics.

This has been an exciting year for science and new therapies.  Proteomics tools are taking us further into the frontier of biology, adding much more understanding to what we’ve learned in genomics.   New “supercharged” killer cells have surprisingly been effective against neurological degenerative diseases.   A new CRISPR-based gene therapy was approved this year.  (Watch for our upcoming interview on this as we review gene-edited therapies with author and journalist Kevin Davies.)

We recently attended the Personalized Medicine Coalition conference, where we booked a dozen new interviews with those who are leading the charge in precision medicine.  These are investors, CEOs, patients, and entrepreneurs committed to bringing the latest discoveries in biology to medicine for the better health of all.

Despite all the layoffs and restructuring this year, breakthroughs continue to make it to patients.  Early cancer detection tests are becoming mainstream.  MRD testing is changing the treatment of cancer.  The future is bright for precision medicine, and we’ll be here to cover every moment of it.

We aim to go into the new year with 500 paying subscribers, and we have about 120 to go.   If you haven’t already, please consider pledging just $10 a month, the price of a couple of coffees, to book your front-row seat to the Century of Biology! Or consider becoming a Mendelspod Founding Member if you’d like to contribute more.

From the two of us to all of you, we wish you the best of the season and a happy New Year!

Theral and Ayanna